Alphagan

(Brimonidine Tartrate)

Phase 2Small molecule

Brimonidine is used to treat high eye pressure in glaucoma patients and to reduce redness and flushing in the face caused by rosacea.[1] Alphagan is currently being investigated across 5 indications[3], with its most advanced program in Phase 2.[1]

Alphagan is one of 95 small molecule programs targeting Glaucoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlaucomaUnknown

RosaceaUnknown

HypertensionUnknown

Abnormality of the SkinUnknown

FolliculitisRecruiting

GlaucomaPreclinical

Unknown

RosaceaPreclinical

Unknown

HypertensionPreclinical

Unknown

Abnormality of the SkinPreclinical

Unknown

FolliculitisPhase 2

Recruiting

Competition

Competitive Landscape

157 competitors in Hypertension

#DrugCompanyPhaseTrials

Foundayo

Eli Lilly

Phase 3

3 2

Nitrostat

VViatris Specialty LLC

Phase 3

5 3

Alka-Seltzer

AAbbott

Phase 3

1 4

Alphagan

AbbVie

Phase 2

24 5

Minocycline /d

UUniversity of Florida

Phase 3

1 6

SGLT2

PProf. Dr. med. Ingo Eitel

Phase 3

1 7

Avastin

Roche

Preclinical

1 8

Winrevair

Merck & Co.

Preclinical

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 10

Nipride

EExela Pharma Sciences, LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Folliculitis

NCT06818058

Clinical

Trials by Indication[1]

Glaucoma2 trials

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

Completed·WWills Eye·Phase 4·NCT03323164·35 enrolled

Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Unknown status·—·Phase 4·NCT04647461·61 enrolled

Erythema2 trials

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

Completed·GGalderma Brasil Ltda.·Phase 4·NCT02856919·101 enrolled

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Withdrawn· Biogen logo

Biogen·Phase 4·NCT02568111

Eye Disease2 trials

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

Completed·OOcugen·Phase 3·NCT03785340·252 enrolled

Dry Eye Disease Study With Brimonidine

Completed·OOcugen·Phase 2·NCT03418727·84 enrolled

Ocular Hypertension2 trials

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Completed· AbbVie logo

AbbVie·N/A·NCT01229462·238 enrolled

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed·AAlcon Research·Phase 3·NCT00061529

Graft Vs Host Disease1 trial

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Terminated·OOcugen·Phase 3·NCT03591874·59 enrolled

15 more indications

CAR1 trial

Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients

Unknown status·OOptall Vision·Phase 1·NCT05001243·11 enrolled

Flushing1 trial

Treatment of Asian Flushing Syndrome With Topical Alpha Agonists

Completed·UUniversity of California, San Francisco·Phase 1·NCT03497442·20 enrolled

Pediatric1 trial

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

Completed·BBausch & Lomb Incorporated·Phase 3·NCT01959243·507 enrolled

Open-Angle Glaucoma1 trial

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma

Completed·—·Phase 4·NCT03966560·96 enrolled

Hand-foot syndrome1 trial

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

Terminated·HHeinrich-Heine University, Duesseldorf·Phase 2·NCT03173365·2 enrolled

Tics1 trial

Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.

Completed·BBausch & Lomb Incorporated·Phase 1·NCT02039765·12 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

Completed·BBausch & Lomb Incorporated·Phase 3·NCT01959230·60 enrolled

Presbyopia1 trial

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Completed·VVisus Therapeutics·Phase 3·NCT05270863·182 enrolled

Folliculitis1 trial

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

Recruiting·TTarian Pharma·Phase 2·NCT06818058·60 enrolled

Rosacea1 trial

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

Completed· LEO Pharma logo

LEO Pharma··NCT02602470·206 enrolled

Safety and Efficacy1 trial

Evaluation of Safety and Efficacy of PDP-716

Completed· Sun Pharma Advanced Research Company Limited logo

Sun Pharma Advanced Research Company Limited·Phase 3·NCT03450629·682 enrolled

Vitrectomy1 trial

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

Completed· AbbVie logo

AbbVie·Phase 1·NCT01229410·24 enrolled

Retinitis Pigmentosa1 trial

An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa

Completed· AbbVie logo

AbbVie·Phase 1/2·NCT00661479·21 enrolled

Age-Related Macular Degeneration1 trial

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

Completed· AbbVie logo

AbbVie·Phase 2·NCT00658619·119 enrolled

Treatment1 trial

Pupil Dilation for Treatment of IFIS

Completed·—·Phase 2·NCT03760185·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Brimonidine Tartrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Brimonidine Tartrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Brimonidine Tartrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Adrenergic Receptor Alpha-2 Agonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Alphagan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Glaucoma2 trials

Erythema2 trials

Eye Disease2 trials

Ocular Hypertension2 trials

Graft Vs Host Disease1 trial

CAR1 trial

Flushing1 trial

Pediatric1 trial

Open-Angle Glaucoma1 trial

Hand-foot syndrome1 trial

Tics1 trial

Efficacy and Safety1 trial

Presbyopia1 trial

Folliculitis1 trial

Rosacea1 trial

Safety and Efficacy1 trial

Vitrectomy1 trial

Retinitis Pigmentosa1 trial

Age-Related Macular Degeneration1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News